Dermatology
News
Listen up: Acoustic device useful for diabetic foot ulcers
New treatment, similar to lithotripsy, aims to boost healing by stimulating cells through acoustic pulses
Latest News
Systemic corticosteroids not recommended for long-term treatment of eczema
The adverse effects of systemic corticosteroids for atopic dermatitis are of particular concern due to the potential for growth retardation in...
Latest News
Minorities less likely to seek treatment for psoriasis
“While psoriasis is less common among minorities than whites, minorities may suffer from a larger burden of disease yet have fewer visits.”
From the Journals
Hydrochlorothiazide use linked to higher skin cancer risk
The common diuretic hydrochlorothiazide is linked to a dose-dependent increased risk of nonmelanoma skin cancer, in particular, squamous cell...
News from the FDA/CDC
FDA approves topical antibiotic for impetigo infections
Ozenoxacin is effective against common bacterial infections as well as methicillin-resistant Staphylococcus aureus (MRSA).
News
FDA approves Eskata for treatment of raised SKs
Topical solution should be used only in the office of a health care provider, not in the home.
From the Journals
Acne severity shows negative impact on women’s self esteem
The literature review provided evidence that subjective, but not objective, perceptions of acne severity affected self-esteem.
News
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
It is the third biosimilar of Remicade to be approved by the FDA.
Conference Coverage
JAK inhibitors for atopic dermatitis might hit JAK-pot
GENEVA –Three positive phase 2 trials of JAK inhibitors in patients with atopic dermatitis generated excitement at the EADV congress.
From the Journals
Obesity an independent risk factor for rosacea in cohort study of U.S. women
Previous epidemiologic studies examining the interaction between obesity and rosacea have shown inconsistent results.
From the Journals
Biosimilars and sources show mostly parallel safety profiles
Infliximab was the only active substance with more than one difference in safety concerns between the biosimilar and originator.